Comparison of Efficacy and Safety of Teneligliptin Versus Sitagliptin as Add on to Metformin in Type 2 Diabetes Mellitus at Jlnmc, Bhagalpur, Bihar

Abstract

Introduction Diabetes mellitus (DM) is a leading cause of mortality and an increasing health burden with a prevalence of 8.3% globally and 9.1% in India (IDF). Prevention of complications and improving quality of life are the principle goals in its management. DPP-4 inhibitors have a potential vasoprotective effect mediated by stromal cell derived factor-1a. Teneligliptin a novel, highly selective, more potent agent compared to Sitagliptin provides sustained glycaemic control, decreases cardiovascular complications, has additional beneficial pleiotropic metabolic effects and also safe in renal impairment. Objective To evaluate the glycaemic and non-glycaemic effects of Teneligliptin vs Sitagliptin as add on therapy to metformin. Materials and methods 60 subjects with T2DM who failed to achieve glycaemic control with metformin (500mg TID) alone for 3 months were randomized in 1:1 ratio to receive Teneligliptin 20mg OD and Sitagliptin 100mg OD as add on therapy. Patients were followed up at 4, 8 and 12 weeks for glycaemic and non-glycaemic effects. Adverse drug reactions (ADRs), if any were recorded and graded according to severity. Results There was a statistically significant decrease in FBS (p<0.05, p<0.001) and PPBS (p<0.01, p<0.001) in patients treated with Teneligliptin on week 8 & week 12 from baseline compared to those treated with Sitagliptin. The reduction in HbA1c (p<0.0001), LDL-CH (p<0.0001) & TC (p<0.001) on week 12 from baseline was also significantly more in the Teneligliptin group. Conclusion Teneligliptin may be an effective and safe treatment option in reducing both glycaemic and non-glycaemic parameters as an add-on therapy in Type 2 DM with good patient tolerability.